Tags : Bristol-Myers

Pharma

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Shots: Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction with the put option. The transaction is expected to close in H1’19 The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform UPSA develops and delivers medicines in multiple therapeutic […]Read More

Regulatory

Bristol-Myers’ Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute

Shots: The CHMP (EMA) recommendation is based on P-II CA180-372 (NCT01460160) study assessing Sprycel + CT in pediatric patients with newly diagnosed +ve acute lymphoblastic leukemia (ALL) Sprycel received the US FDA’s and EU’s approval to treat pediatric patients with +ve chronic myeloid leukemia in chronic phase (CML-CP) in Nov, 2017 & July, 2018 respectively Sprycel is a tyrosine kinase inhibitor, […]Read More